Patents by Inventor Trudy M. Forte

Trudy M. Forte has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Synthetic LDL as targeted drug delivery vehicle
    Patent number: 8252338
    Abstract: The present invention provides a synthetic LDL nanoparticle comprising a lipid moiety and a synthetic chimeric peptide so as to be capable of binding the LDL receptor. The synthetic LDL nanoparticle of the present invention is capable of incorporating and targeting therapeutics to cells expressing the LDL receptor for diseases associated with the expression of the LDL receptor such as central nervous system diseases. The invention further provides methods of using such synthetic LDL nanoparticles.
    Type: Grant
    Filed: November 13, 2006
    Date of Patent: August 28, 2012
    Assignees: The Regents of the University of California, Children's Hospital & Research Center Oakland
    Inventors: Trudy M. Forte, Mina Nikanjam
  • Synthetic LDL as Targeted Drug Delivery Vehicle
    Publication number: 20100047163
    Abstract: The present invention provides a synthetic LDL nanoparticle comprising a lipid moiety and a synthetic chimeric peptide so s to be capable of binding the LDL receptor. The synthetic LDL nanoparticle of the present invention is capable of c incorporating and targeting therapeutics for diseases associated with the expression of the LDL receptor. The invention further provides methods of using such synthetic LDL nanoparticles.
    Type: Application
    Filed: November 13, 2006
    Publication date: February 25, 2010
    Applicants: LAWRENCE BERKELEY NATIONAL LABORATORY, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, CHILDREN'S HOSPITAL & RESEARCH CENTER OAKLAND
    Inventors: Trudy M. Forte, Mina Nikanjam
  • Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
    Patent number: 7223726
    Abstract: Functional Apolipoprotein A-I mutant proteins, having one or more cysteine substitutions and polynucleotides encoding same, can be used to modulate paraoxonase's arylesterase activity. These ApoA-I mutant proteins can be used as therapeutic agents to combat cardiovascular disease, atherosclerosis, acute phase response and other inflammatory related diseases. The invention also includes modifications and optimizations of the ApoA-I nucleotide sequence for purposes of increasing protein expression and optimization.
    Type: Grant
    Filed: January 14, 2003
    Date of Patent: May 29, 2007
    Assignee: The Regents of the University of California
    Inventors: Michael N. Oda, Trudy M. Forte
  • Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
    Publication number: 20030181372
    Abstract: Functional Apolipoprotein A-I mutant proteins, having one or more cysteine substitutions and polynucleotides encoding same, can be used to modulate paraoxonase's arylesterase activity. These ApoA-I mutant proteins can be used as therapeutic agents to combat cardiovascular disease, atherosclerosis, acute phase response and other inflammatory related diseases. The invention also includes modifications and optimizations of the ApoA-I nucleotide sequence for purposes of increasing protein expression and optimization.
    Type: Application
    Filed: January 14, 2003
    Publication date: September 25, 2003
    Applicant: The Regents of the University of California
    Inventors: Michael N. Oda, Trudy M. Forte